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Heart transplantation is a lifesaving procedure for patients with end-stage heart failure1,2; however, despite much 
improvement in surgical approaches and patient management, 
the late outcome of graft survival has not improved in the past 
decade.2,3 Although current immunosuppressive regimens have 
brought about a drastic reduction in acute rejection episodes,3 
the rate of chronic rejection leading to cardiac transplant 
loss has not improved, and the risk of immunosuppression-
related graft toxicity, cancer, infections, and coronary 
allograft vasculopathy remains high.2–4 Thus, to improve 
transplantation outcomes and lessen the need for life-long 
immunosuppression, it is critical to continue the development 
of novel immunomodulatory strategies to promote stable graft 
acceptance.5 The alloimmune response involves complex 
immunologic interactions between inflammatory mechanisms, 
which cause graft rejection, and anti-inflammatory 
mechanisms, which promote tolerance of the graft.6 Blocking 
pathogenic and upregulating tolerogenic mechanisms has 
been shown to result in enhanced graft survival.7 To achieve 
complete activation of T cells during the alloimmune response, 
Background—Heart transplantation is a lifesaving procedure for patients with end-stage heart failure. Despite much effort 
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and regulates T-cell activation. Novel clinical-grade P2X7R inhibitors are available, rendering the targeting of P2X7R a 
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inhibition of STAT3 phosphorylation in T cells, thus leading to a reduced transplant infiltrate and coronaropathy. In vitro 
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delivery of signal 1 (engagement of the T-cell receptor [TCR] 
with the major histocompatibility complex-peptide complex 
on antigen-presenting cells) and signal 2 (interaction of 
costimulatory molecules) is required.8,9 However, other 
players, including innate immunity and inflammation, have 
been recently recognized to exert a major role.10,11 The purine 
ATP, released during cell damage/inflammation, may serve as 
1 such signal. ATP is present at high concentrations within the 
cells,12 and it is thus released following cell damage or death13; 
moreover, ATP can be secreted by immune cells following 
activation.14,15 ATP is abundant at sites of inflammation and 
is sensed by ionotropic purinergic P2X receptors (7 receptors 
named P2X1R to P2X7R, or P2XsR).16–18 P2XsR have been 
associated in vitro to T-cell activation and interleukin (IL)-2 
production14,19–21 and in vivo to graft-versus-host disease.18 
Recently, ATP has been shown to play a major role in T-helper 
cell (Th17) differentiation22 and regulatory T cell (Treg) 
inhibition,23 and T-helper cell 1 (Th1) and Th17 immune 
responses have been associated with organ rejection.24,25 Indeed, 
natural ATP/P2XsR inhibitors with the ability to hydrolyze 
ATP are expressed on the cellular plasma membrane (eg, the 
ectonucleotidases CD39 and CD73).26 Novel P2X7R inhibitors 
are available for human use, including periodate-oxidized ATP 
(oATP), CE224,535, AZD9056, and GSK1482160, thereby 
rendering P2X7R targeting a potential path to be tested in 
transplantation.27 oATP, a small Schiff base molecule, is 
an irreversible antagonist of P2X7R owing to the selective 
modification of lysine residues that occurs in the vicinity of 
the ATP-binding site28; oATP has also been proposed to exert 
additional inhibitory effect on the other purinergic receptors.20 
We aim to unveil the largely unknown role of P2X7R in heart 
transplantation and to target the ionotropic purinergic receptor 
P2X7R to achieve tolerance toward cardiac transplants.
Clinical Perspective on p 475
Materials and Methods
Immunologic Methods can be found in the online-only Data 
Supplement Materials.
Patients
Cardiac samples were obtained from the right side of the interven-
tricular septum of cardiac transplant recipients at Niguarda Ca’ 
Granda Hospital, Milan, Italy. Samples were formalin-fixed, paraffin-
embedded, sectioned, and histologically graded by a cardiac patholo-
gist according to the 2005 International Society for Heart and Lung 
Transplantation criteria.29 Characteristics of patients and the immuno-
suppressive regimen30 are depicted in the Table.
Mice
C57BL/6, BALB/c, C57BL/6 P2X7−/−, B6.C-H2bm12 (bm12), and 
C57BL/6 Rag1−/− mice of various ages were obtained from the 
Jackson Laboratory. ABM TCR-Tg mice have been described previ-
ously31 and were maintained as a breeding colony in our animal facil-
ity. All mice were cared for and used in accordance with institutional 
guidelines. Protocols were approved by the Harvard Medical School 
Animal Care and Use Committee.
Interventional Studies
Mice were injected intraperitoneally with oATP (Medestea srl) 250 µg/d 
intraperitoneally for 14 days and Colivelin (Tocris, Minneapolis, MN) 7 
nmol/L per day for 7 days. In vitro assays were performed in the pres-
ence of varying concentrations of oATP, NF-449 (P2X1R inhibitor), and 
5-BDBD (P2X4R inhibitor) from Tocris Bioscience (Bristol, UK)
Heart Transplantation
Vascularized cardiac allografts were transplanted intra-abdominally 
by using microsurgical techniques as described by Corry et al.32 
Rejection was determined as complete cessation of cardiac contrac-
tility and was confirmed by direct visualization.
Histology and Immunohistochemistry
Immunohistochemistry was performed with 5-μm-thick formalin-
fixed, paraffin-embedded tissue section. Photomicrographs (400×) 
were taken by using an Olympus BX41 microscope (Center Valley, 
PA). The following primary antibodies were used: anti-Mac2, 
anti-CD3 (Cell Marque, CA), anti-CD20, anti CD68 (Dako, Glostrup, 
Denmark), and anti-P2X7 (Alomone Labs, Jerusalem, Israel). As 
isotype control for anti-P2X7R, normal rabbit immunoglobulin G 
(R&D Systems, MN) was used. Graft histology was evaluated by an 
expert pathologist and was quantified as follows: (i) heart coronary 
vasculopathy: 0, normal arteries; 1, mild arterial wall infiltration; 
2, heavy arterial wall infiltration with partial luminal occlusion; 3, 
complete luminal occlusion; and (ii) heart cell infiltrate: 0, no cell 
infiltrate; 1, mild cell infiltrate; 2, medium cell infiltrate; 3, heavy 
cell infiltrate.
Table. Patient Characteristics 
Year of transplantation 2011
Number of transplantations 23
Sex (M/F) 16/7
Age, y 47±15
End-stage heart failure etiology, n (%)
 Postischemic 6 (26.9)
 Dilated CMP 11 (47.8)
 Valvular CMP 2 (8.7)
 Retransplantation 1 (4.3)
 Hypertrophic CMP 1 (4.3)
 Postcorrection congenital CMP 1 (4.3)
  CMP associated with Steinert myotonic 
dystrophy syndrome
1 (4.3)
Initial immunosuppressive regimen*
 Induction ATG
 Maintenance Csa+methylprednisolone+mycophe
nolate mofetil
Acute graft rejection episodes,† n (%) 10 (43.8)
Mortality, n (%)
  Acute rejection 3R (50 d after 
transplantation)‡
1 (4.3)
  Multiorgan failure (70 d after 
transplantation)
1 (4.3)
Donor
 Age, y 45±13
 Ischemia, min 185±53
Data are expressed as mean±SD. CMP indicates cardiomyopathy; ATG, 
thymoglobulin; and Csa, cyclosporine; P2X7R, purinergic receptor P2X7.
*Immunosuppressive regimen was subsequently tuned according to patient 
conditions.30
†Requiring intravenous steroids treatment.
‡Assessed for P2X7R expression.
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Confocal Microscopy
Immunofluorescence samples were observed by using a confocal 
system (LSM 510 Meta scan head integrated with the Axiovert 200 
mol/L inverted microscope; Carl Zeiss, Jena, Germany) with a 63× 
oil objective. Images were acquired in multitrack mode with the use 
of consecutive and independent optical pathways.
Quantitative Real-Time Polymerase Chain Reaction
RNA was purified by using an RNeasy kit (Qiagen, CA) and was 
reverse-transcribed into cDNA by using Superscript III (Invitrogen, 
CA). Transcripts were amplified using a 7300 Real-Time polymerase 
chain reaction (PCR) System (Applied Biosystems, CA); primers 
were obtained from Applied Biosystems. Real-time PCR products 
were normalized to copies of GAPDH.
Flow Cytometry and Intracellular Cytokine 
Staining
Annexin V Apoptosis Detection Kit, anti-mouse CD4, CD8, CD25, 
CD44, CD62L, interferon-γ (IFN-γ), IL-17, and FoxP3, were pur-
chased from BD Biosciences and eBioscience (San Diego, CA), anti-
mouse P2X7 was purchased from Alomone Labs.33
Phoshoprotein Determination
Cells were lysed by using 30 µL of lysis buffer provided with the 
Millipore MILLIPLEX MAP kit (Millipore, MA) supplemented with 
protease inhibitor. The Millipore MILLIPLEX MAP Cell Signaling 
Assay and the Luminex xMAP platform were used according to the 
manufacturer’s protocol (Millipore).
Western Blot
Total protein concentration in cell lysates was measured by using a 
Bradford assay (Bio-rad, CA). Proteins were resolved on an sodium 
dodecyl sulfate polyacrylamide gel via electrophoresis and were 
transferred to a nitrocellulose membrane and then incubated with pri-
mary rabbit anti-P2X1, anti-P2X4, and anti-P2X7 receptor antibodies 
(Alomone Labs), anti-T-bet/Tbx21 and anti-ROR-γ (Abcam, MA), 
anti-Stat3 and anti-Phospho Stat3 (Ser727) (Cell Signaling, MA), 
and GAPDH (Cell Signaling), as well. Densitometric quantification 
of band intensity was analyzed by using ImageJ software and was 
normalized to GAPDH-loading control expression.
Statistical Analysis
Data are expressed as means±standard error of mean. Statistical dif-
ferences in survival times were determined by the use of Kaplan-
Meier curves, followed by the log-rank test. Analyses were performed 
in SAS (SAS Institute, NC, v. 9.3). All data were transformed to their 
base 10 logarithms for their statistical evaluation. The Levene test 
was used to test homogeneity of variances. Whenever unequal vari-
ances existed in the comparison of 3 groups or more, Welch analysis 
of variance with appropriate degrees of freedom (≥2) was used to 
compare the groups. Subsequently, post hoc analysis of Welch t test 
with Bonferroni correction was applied. In the 2-group comparison, 
Levene test and Welch t test were used. P<0.05 was considered sig-
nificant. Graphs were generated by using GraphPad Prism version 5.0 
(GraphPad Software).
Results
P2X7R Is Induced in Cardiac Transplants During 
the Alloimmune Response
We evaluated the expression of P2XsR in cardiac trans-
plants in vivo. Hearts from BALB/c (H-2d) mice were het-
erotopically transplanted into C57BL/6 (H-2b) mice, and 
cardiac transplants and splenocytes were harvested at day 7 
after transplantation (the average time for cardiac transplant 
rejection). Expression of the P2XsR was compared with 
baseline values (ie, untransplanted BALB/c hearts or naïve 
C57BL/6 splenocytes) by real-time PCR. Upregulation of 
P2X1R (14-fold increase), P2X4R (4-fold increase), and 
P2X7R (9-fold increase) receptors was observed in the 
cardiac transplants (Figure 1A, 1D, and 1G). Conversely, 
no induction of P2XsR was observed in splenocytes of 
cardiac-transplanted mice (data not shown). To dissect the 
specific effect of the alloimmune response from effects of 
ischemia-reperfusion injury and nonspecific inflammation, 
we compared P2XsR expression in allografts and syngrafts 
(C57BL/6 hearts into C57BL/6 recipients). P2X1R, P2X4R, 
and P2X7R were also upregulated in syngeneic heart trans-
plants in comparison with baseline (Figure 1A, 1D, and 1G); 
however, only P2X7R was significantly increased in alloge-
neic in comparison with syngeneic transplants (Figure 1G). 
P2X2R, P2X3R, P2X5R, and P2X6R (Figure 1B, 1C, 1E, 
and 1F) expression was unchanged in both cardiac syngrafts 
and allografts in comparison with baseline. We then assessed 
which cell type was responsible for the P2X7R upregula-
tion observed with the use of immunohistochemical analy-
sis. P2X7R staining was negative in untransplanted BALB/c 
hearts (data not shown), whereas clear positive staining was 
evident in the mononuclear immune cell infiltrate of cardiac 
transplants harvested at day 7 (Figure 1H1 and 1H2); cardio-
myocytes and other parenchymal cells appeared to be nega-
tive for P2X7R staining. We also confirmed complete overlap 
between CD3+ T cells and P2X7R expression via immuno-
fluorescence and confocal microscopy (Figure 1I1 through 
1I3). In addition, we evaluated whether P2X7R upregulation 
was a phenomenon present in patients (Table). When we ana-
lyzed the graft infiltrate in patients experiencing acute heart 
rejection, clear expression of P2X7R was observed (Figure 
1J1 and 1J2), and confocal imaging confirmed that P2X7R 
staining overlapped with CD3 staining (Figure 1K1 through 
1K3). No colocalization was evident between P2X7R expres-
sion and CD20+ B cells (L) or CD68+ macrophages (M).
In Vivo Short-term P2X7R Targeting Prevents 
Cardiac Transplant Rejection, Abrogates the Th1/
Th17 Immune Response, and Reduces Effector T 
Cells in Mice
We next tested the effect of P2X7R targeting in preventing 
cardiac transplant rejection by using the P2X7R inhibitor 
oATP. Untreated C57BL/6 mice transplanted with BALB/c 
hearts (fully mismatched) invariably rejected grafts within 
7 days (mean survival time of 7 days; Figure 2A). P2X7R 
targeting with the use of the short-term treatment of oATP 
(250 mg oATP intraperitoneally daily for 14 days) induced 
long-term cardiac transplant survival (>100 days) in 80% 
of recipients (Figure 2A). To evaluate the effect of P2X7R 
targeting on the immune system of cardiac-transplanted 
mice, splenocytes were harvested at days 7 and 100 
posttransplantation and were challenged with BALB/c-
irradiated splenocytes in an enzyme-linked immunosorbent 
spot (ELISPOT) assay. Reduced numbers of IFN-γ–
producing cells (Figure 2B) and increased numbers of IL-4–
producing cells (Figure 2C) were observed in oATP-treated 
in comparison with untreated mice at day 7; a stronger effect 
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was observed at day 100 in oATP-treated mice (Figure 2B 
and 2C). The percentages of peripheral CD4+ effector T 
cells (CD4+CD44hiCD62Llow, or CD4+ Teffs), CD8+ effector 
T cells (CD8+CD44hiCD62Llow, or CD8+ Teffs), regulatory 
T cells (CD4+CD25+FoxP3+, or Tregs), and Th17 cells 
(CD4+IL17+) were quantified in cardiac-transplanted mice 
by flow cytometric analysis. The percentages of CD4+ Teffs 
(Figure 2D) and CD8+ Teffs (Figure 2E) were reduced by 
in vivo short-term P2X7R targeting in mice at days 7 and 
100 posttransplantation in comparison with untreated mice. 
The percentage of Th17 cells was similarly reduced (Figure 
2F). No differences in the percentage of Tregs were observed 
between treated and untreated mice at day 7, but an increase 
was observed at day 100 (Figure 2G). Thus, we show that 
short-term P2X7R targeting reshapes the immune system and 
induces hyporesponsiveness toward donor antigens.
In Vivo Short-term P2X7R Targeting Induces 
Anergy Toward Donor-Derived Alloantigens 
but Preserves Immunocompetence in Cardiac-
Transplanted Mice
To assess whether long-term cardiac transplant survival was 
associated with active regulation toward alloantigens or with 
reduced immunocompetence, hearts from BALB/c mice were 
transplanted into immunodeficient C57BL/6 Rag−/− mice 
together with splenocytes obtained from cardiac transplant 
recipients. Graft rejection was observed within 20 days in 
mice adoptively transferred with naïve C57BL/6 splenocytes, 
and no protection was observed when splenocytes obtained 
from mice with long-term graft function were coadoptively 
transferred with naïve splenocytes (Figure 2H). Conversely, 
prolonged graft survival >50 days was observed when spleno-
cytes obtained from cardiac-transplanted mice with long-term 
Figure 1. Syngeneic C57BL/6 (Syngeneic Tx) and allogeneic BALB/c cardiac transplants (Allogeneic Tx) were harvested from C57BL/6 
recipient mice 7 days posttransplantation, and P2XsR mRNA levels were compared with untransplanted BALB/c hearts (Baseline). An 
upregulation of P2X1R (A), P2X4R (D), and P2X7R (G) expression in both syngrafts and allografts was evident in comparison with baseline 
(n=3, *P<0.05, **P<0.01); greater P2X7R upregulation was observed in allogeneic than in syngeneic heart transplants (n=3, #P<0.05; G). 
No upregulation for P2X2R (B), P2X3R (C), P2X5R (E), and P2X6R (F) was observed. Substantial infiltration was observed at day 7 after 
transplantation in allografts (H1). Immunohistochemistry revealed that mononuclear infiltrating cells were positive for P2X7R expression 
(H2), whereas myocytes, endothelial cells, and fibroblast showed no expression (H2). Immunofluorescence confirmed complete over-
lapping between CD3+ T cells and P2X7R expression (I1 through I3). P2X7R was expressed in lymphocytes infiltrating human cardiac 
transplants undergoing acute rejection as well (J1 and J2). Complete overlapping between CD3+ T cells and P2X7R was also demon-
strated (K1 through K3), whereas no colocalization was observed between P2X7R (red; L and M) and CD20+ B cells (green, L) or CD68+ 
macrophages (green, M). P2X1R indicates purinergic receptor P2X1; P2X2R, purinergic receptor P2X2; P2X3R, purinergic receptor P2X3; 
P2X4R, purinergic receptor P2X4; P2X5R, purinergic receptor P2X5; P2X6R, purinergic receptor P2X6; P2X7R, purinergic receptor P2X7; 
and H&E, hematoxylin and eosin. 
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graft function were adoptively transferred (Figure 2H). These 
data suggest that in vivo short-term P2X7R targeting is more 
likely to induce anergy toward graft antigens than to induce 
active regulation. We then tested the immunocompetence of 
treated mice at day 100 after transplantation. Naïve C57BL/6 
mice or oATP-treated mice were immunized with ovalbumin, 
and splenocytes were rechallenged in vitro 7 days later; no dif-
ferences in numbers of IFN-γ–producing cells were observed 
(Figure 2I). These data demonstrate that in vivo short-term 
P2X7R targeting promotes anergy toward graft antigens while 
maintaining immunocompetence.
In Vivo Short-term P2X7R Targeting Reduces 
Infiltration and Th1/Th17 Transcripts in Cardiac 
Transplants
To further investigate the effect of in vivo short-term P2X7R 
targeting on the antigraft response, we analyzed cardiac 
transplant infiltrate in oATP-treated and untreated mice. 
Histological analysis performed at day 7 posttransplantation 
revealed a reduced CD3+ T cell infiltrate in treated (Figure 3B1 
and 3B2) in comparison with untreated mice (Figure 3A1 and 
3A2), and semiquantitative analysis confirmed a reduction in 
degree of infiltration and of coronary vasculopathy (Figure 
3C and 3D). To investigate the effect of oATP treatment on 
Th1 and Th17 cells infiltrating the cardiac transplant, we 
analyzed allograft mRNA expression of T-bet (a Th1 cell 
marker) and of ROR-γ (a Th17 cell marker); both markers 
appeared substantially reduced in oATP-treated mice (Figure 
3E and 3F), but no difference in the Th2 transcript GATA3 
was observed (data not shown). At day 100, cardiac allografts 
were well preserved and free from infiltration in oATP-treated 
mice (Figure 3G1 and 3G2). Thus, pathological analysis 
confirms that P2X7R targeting preserves cardiac transplant 
morphology.
Figure 2. P2X7R inhibition with oATP in the BALB/c into C57BL/6 cardiac transplantation model prevented transplant rejection in 80% of 
transplants (n=15, ***P<0.001 versus Untreated; A). When recipient splenocytes were rechallenged with donor splenocytes in an ELISPOT 
assay at day 7 after transplantation, they displayed fewer IFN-γ–producing cells (n=5, ***P<0.001 versus Untreated day 7; B) and more IL-
4–producing cells (n=5, ***P<0.001 versus Untreated day 7; C) with further polarization at day 100 (n=5, IFN-γ: ###P<0.001; IL-4: #P<0.05 
versus Untreated and oATP-treated day 7; B and C). A significant reduction in the number of CD4+ Teffs (n=5, *P<0.05, **P<0.01 versus 
Untreated day 7; D), CD8+ Teffs (n=5, ***P<0.001 versus Untreated day 7; E), and IL-17+CD4+ T cells (n=5, *P<0.05 versus Untreated 
day 7; F) was observed at days 7 and 100 in oATP-treated mice. No differences in the percentages of peripheral Tregs were observed 
between oATP-treated and untreated mice at day 7, whereas an increase in the Treg population was seen at day 100 (n=5, ***P<0.001 
versus Untreated day 7, ###P<0.001 versus oATP-treated day 7; G). BALB/c cardiac transplant rejection was observed in C57BL/6 
Rag−/− mice adoptively transferred with naïve C57BL/6 splenocytes alone (Controls) or in combination with splenocytes from oATP-treated 
mice, whereas prolonged graft survival was observed when splenocytes from oATP-treated mice were transferred alone (n=4, ***P<0.001 
versus Controls; H). Immunocompetence was preserved in oATP-treated mice as assessed by in vitro ovalbumin response after in vivo 
immunization (n=3, ***P<0.001 versus Unimmunized; I). ELISPOT indicates enzyme-linked immunosorbent spot; IFN-γ, interferon γ; oATP, 
periodate-oxidized ATP; IL-4, interleukin 4; and IL-17, interleukin 17.
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In Vivo Short-term P2X7R Targeting Inhibits the 
Expansion of Alloantigen-specific T Cells
To address whether the inhibition of the effector T-cell 
compartment is related to reduced priming and expansion of 
alloreactive T cells or to their increased apoptosis, we tracked 
alloreactive-specific T cells in a transgenic model of cardiac 
transplantation. Bm12 hearts were transplanted into C57BL/6 
Rag−/− mice, and 3 × 106 ABM CD4+ TCR-Tg T cells (specific 
for bm12 major histocompatibility complex class II antigens) 
were subsequently adoptively transferred into cardiac 
transplant recipients.31 Seven days posttransplantation, 
reduced numbers of ABM CD4+ TCR-Tg T cells were evident 
in oATP-treated in comparison with untreated mice (Figure 
4A). A marked reduction in the numbers of Teffs and Th17 
cells within the Tg population was also observed in oATP-
treated in comparison with untreated mice (Figure 4B and 
4C, respectively). We then examined whether the reduced 
number of alloantigen-specific CD4+ T cells was due to 
reduced proliferation or to increased apoptosis. A decrease 
in ABM CD4+ TCR-Tg T-cell proliferation, as assessed 
by the dilution of the intracellular dye carboxyfluorescein 
diacetate succinimidyl ester, was observed in oATP-treated 
(Figure 4E) in comparison with untreated mice (Figure 4D), 
without substantial differences in TCR-Tg T-cell apoptosis 
4 days following adoptive transfer (Figure 4F and 4G). 
The results obtained demonstrate that the inhibition of the 
effector cell compartment on oATP treatment is not mediated 
by a significant increase in apoptosis, but rather by decreased 
proliferation.
P2X7R is Required for oATP to Prolong Cardiac 
Transplant Survival
oATP has been proposed to exert secondary immunomodu-
latory mechanisms, primarily related to the inhibition of the 
remaining P2XsR.20 To verify that the effect on the preven-
tion of cardiac transplant rejection was predominantly due 
to P2X7R inhibition, we made use of the P2X7R−/− C57BL/6 
mouse model. BALB/c hearts were transplanted into 
P2X7R−/− mice, and cardiac transplant survival was compared 
with that of wild-type recipients. A significant prolongation of 
cardiac transplant survival was observed in P2X7R−/− recipi-
ents, confirming the role of P2X7R in allograft rejection (Fig-
ure 5A). The ability of oATP to prolong cardiac transplant 
survival was severely altered in P2X7R−/− mice, suggesting 
that, in the context of cardiac alloimmune response, oATP 
acts mainly, although not exclusively, through P2X7R (Fig-
ure 5A). Moreover, these data suggest that compensatory 
mechanisms exist in P2X7R−/− mice; indeed, ATP has been 
shown to signal through other P2XsR, in particular, through 
P2X1R and P2X4R in the context of T-cell activation and 
immune function.21 We thus analyzed CD4+ T cells obtained 
from P2X7R−/− mice by Western blot, and an upregulation 
of P2X1R and P2X4R was observed in comparison with 
wild-type mice (Figure 5B through 5D). Given these data, 
Figure 3. Histological analysis of cardiac transplants at day 7 after transplantation revealed preserved graft parenchyma, reduced artery 
lumen occlusion, and fewer numbers of CD3+ graft-infiltrating cells in oATP-treated (B1 and B2) in comparison with untreated mice (A1 
and A2). Semiquantification of graft infiltrate (n=5, *P<0.05 versus Untreated day 7; C) and coronary vasculopathy (n=5, *P<0.05 versus 
Untreated day 7; D) confirmed the protection conferred by oATP treatment. T-bet (a Th1 marker) (n=3, **P<0.01 versus Untreated day 7; 
E) and ROR-γ (a Th17 marker) (n=3, **P<0.01, versus Untreated day 7; F) transcripts were reduced in oATP-treated in comparison with 
untreated mice. Preserved parenchyma, mild coronary vasculopathy, and very few CD3+ lymphocytes and MAC2+ macrophages were 
observed at 100 days after transplantation in oATP-treated mice with long-term functioning cardiac transplants (G1 and G2). oATP indi-
cates periodate-oxidized ATP; and Th, T-helper cell. 
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we hypothesize that the upregulation of P2X1R and P2X4R 
may partially compensate for P2X7R function in our model. 
Moreover, analysis of T-cell populations in P2X7R−/− mice 
revealed higher percentages of Teff and Treg cells (Figure 5E 
and 5F, respectively), thus demonstrating that genetic deletion 
of P2X7R and the compensatory upregulation of other P2XsR 
exert profound and complex effects on T-cell activation and 
homeostasis.
Figure 4. ABM TCR-Tg CD4+ T cells were injected intraperitoneally into bm12 cardiac-transplanted C57BL/6 Rag−/− mice. Reduced num-
bers of ABM TCR-Tg CD4+ T cells were observed after 7 days in the spleens of oATP-treated in comparison with untreated mice (n=3, 
***P<0.001 versus Untreated day 7; A). A significant reduction in the numbers of CD4+ Teffs (n=3, **P<0.01 versus Untreated day 7; B) and 
Th17 cells (n=3, **P<0.01 versus Untreated day 7; C) was also evident. ABM TCR-Tg CD4+ T cells were then labeled with the intracellular 
dye CFSE before injection and were harvested after 4 days; significant inhibition of proliferation was observed in oATP-treated mice (E) in 
comparison with untreated mice (D). Data are representative of 3 experiments. Similar levels of apoptosis (percentage of AnnexinV+7AAD− 
cells) of ABM TCR-Tg CD4+ T cells were observed in untreated and oATP-treated mice (F and G, respectively, representative of 3 experi-
ments). CFSE indicates carboxyfluorescein diacetate succinimidyl ester; oATP, periodate-oxidized ATP; and TCR, T-cell receptor.
Figure 5. BALB/c hearts were transplanted 
into WT or P2X7R−/− C57BL/6 mice; graft 
survival prolongation was observed in 
P2X7R−/− recipients (*P<0.05 versus WT 
untreated; A); oATP treatment was less 
effective in prolonging cardiac transplant 
survival in P2X7R−/− mice in comparison 
with WT (***P<0.001 versus WT Untreated; 
#P<0.05 versus all; A). Western blot analy-
sis of CD4+ T cells revealed higher P2X1R 
and P2X4R expression in P2X7R−/− than in 
WT mice (n=3, **P<0.01; ***P<0.001 versus 
WT; B through D). Greater numbers of CD4+ 
T effector (n=3; ***P<0.001 versus WT; E) 
and T regulatory cells (n=3; **P<0.01 ver-
sus WT; F) were present in P2X7R−/− than 
in WT mice. WT indicates wild type; oATP, 
periodate-oxidized ATP; P2X1R, purinergic 
receptor P2X1; P2X4R, purinergic recep-
tor P2X4; and P2X7R, purinergic receptor 
P2X7.
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In Vitro P2X7R Targeting Inhibits CD4+ T-Cell 
Activation and Th1/Th17 Differentiation
To address the mechanisms underlying P2X7R targeting-
mediated inhibition of cardiac transplant rejection, we 
analyzed the effect of P2X7R targeting on T-cell activation 
and Th1/Th17 differentiation in vitro. P2X7R was expressed 
on CD4+ and CD8+ T cells isolated from splenocytes, as 
assessed by Western blotting and real-time PCR, with 
higher expression levels observed in CD4+ T cells (Figure 
6A and 6B). We then tested the effect of in vitro P2X7R 
targeting with oATP during CD4+ T-cell activation. First, in 
an ELISPOT assay, naïve CD4+ T cells were stimulated with 
0.5 µg/mL anti-CD3-Ig and anti-CD28-Ig for 24 hours, and, 
when 100 µM oATP was added to cultures, the number of 
IFN-γ–producing CD4+ T cells was significantly reduced in 
comparison with controls (Figure 6C). Second, in a T-cell 
proliferation assay, carboxyfluorescein diacetate succinimidyl 
ester–labeled naïve CD4+ T cells were stimulated for 96 hours 
with 0.5 µg/mL anti-CD3-Ig and anti-CD28-Ig, and treatment 
with 100 µM oATP diminished CD4+ T cell proliferation 
(Figure 6D, lower) in comparison with controls (Figure 6D, 
upper). Expression levels of the P2XsR were not influenced 
by the presence of oATP during anti-CD3-Ig/anti-CD28-Ig 
stimulation (online-only Data Supplement Figure IA). To 
assess whether oATP is specific for P2X7R or whether it also 
induces its effect through the inhibition of other purinergic 
receptors (eg, P2X1R or P2X4R, which have been involved in 
immune function),21 we combined 100 µM oATP with 50 µM 
P2X1R (NF-449) and 50µM P2X4R (5-BDBD) inhibitors; a 
further suppression of anti-CD3-Ig/anti-CD28-Ig–mediated 
IFN-γ production was obtained (Figure 6E). These data 
demonstrate that the concentration of oATP is not (at least 
not completely) blocking P2X1R and P2X4R. We next tested 
the effect of in vitro P2X7R targeting during a Th1/Th17 
generation and differentiation assay. A small percentage of 
naïve Th0 CD4+ T cells (CD4+CD25−) were shown to express 
Figure 6. Greater P2X7R expression was observed in CD4+ in comparison with CD8+ T cells, as assessed by Western blot (A) and real-
time PCR analysis (B) (n=3, *P<0.05 versus CD4+ T cells). Anti-CD3-Ig/anti-CD28-Ig-stimulated CD4+ T cells were used in an ELISPOT 
assay in conjunction with oATP treatment, and a reduction in IFN-γ–producing CD4+ T cells was observed (n=5, **P<0.01 versus Control; 
C). CFSE dilution analysis revealed a lesser number of proliferating CD4+ T cells (D, lower; representative of 3 different experiments) in 
the presence of oATP compared to control (D, upper; representative of 3 different experiments). In an ELISPOT assay, IFN-γ produc-
tion in CD4+ T cells was further inhibited when anti-P2X1R and anti-P2X4R were added (n=5, ***P<0.001 versus oATP; E). Although 
naïve Th0 cells displayed marginal P2X7R expression, when they were differentiated into Th1 or Th17 cells, an upregulation of P2X7R in 
these cells was observed (n=3, *P<0.05 versus naïve Th0; F through I). In our Th1/Th17 differentiation assay, reduced numbers of IFN-γ+ 
(n=4, **P<0.01 versus Control [no oATP]; J and K) and IL-17+ (n=4, *P<0.05 versus Control; L and M) CD4+ T cells were generated in the 
presence of oATP. PCR indicates polymerase chain reaction; IFN-γ, interferon γ; ELISPOT, enzyme-linked immunosorbent spot; CFSE, 
carboxyfluorescein diacetate succinimidyl ester; P2X1R, purinergic receptor P2X1; P2X4R, purinergic receptor P2X4; P2X7R, purinergic 
receptor P2X7; IFN-γ, interferon γ; oATP, periodate-oxidized ATP; IL-17, interleukin 17; and Th, T-helper cell. 
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P2X7R (Figure 6F and 6G); however, when Th0 CD4+ T cells 
were activated and differentiated in the appropriate cytokine 
milieu into Th1 or Th17 cells, an upregulation of P2X7R 
was observed (Figure 6F, 6H, and 6I). P2X7R targeting with 
oATP inhibited Th0 conversion into both Th1 (Figure 6J 
and 6K) and Th17 (Figure 6L and 6M), as assessed by the 
percentage of IFN-γ+ and IL-17+ cells, respectively. We show, 
therefore, that P2X7R targeting through oATP suppresses 
activation, proliferation, and Th1/Th17 differentiation of 
CD4+ T cells. We then further investigated the role of P2X7R 
on T-cell activation and Th1/Th17 differentiation by genetic 
upregulation of P2X7R. P2X7R cDNA was transduced by 
using a pMY-IRES-GFP retroviral vector into CD4+ T cells 
(pmY-P2X7R CD4+ T cells), and upregulation of P2X7R 
expression was confirmed by Western blot (online-only Data 
Supplement Figure IIA). pmY-P2X7R CD4+ T cells were then 
challenged with anti-CD3-Ig/anti-CD28-Ig stimulation in an 
ELISPOT assay. A greater number of IFN-γ–producing cells 
was observed in pmY-P2X7R CD4+ T cells in comparison 
with cells transduced with the empty vector (pmY-mock CD4+ 
T cells) (online-only Data Supplement Figure IIB). In a Th1/
Th17 generation assay, pmY-P2X7R CD4+ T cells seemed to 
display increased differentiation capacity in comparison with 
pmY-mock CD4+ T cells, as assessed by T-bet (online-only 
Data Supplement Figure IIC and IID) and ROR-γ expression 
(online-only Data Supplement Figure IIE and IIF).
In Vitro and In Vivo P2X7R Targeting Inhibits 
STAT3 Phosphorylation
We next assessed which molecular pathway during T-cell 
activation was preferentially inhibited by the targeting of 
P2X7R. Several key components of T-cell receptor signaling 
involved in the alloimmune response34 were examined, and the 
phosphorylation kinetics following in vitro anti-CD3-Ig/anti-
CD28-Ig–mediated CD4+ T-cell activation was evaluated by 
using the Luminex assay.35 Peak phosphorylation for the ana-
lyzed pathways was observed at 30 minutes for JNK/SAPK1 
and at 60 minutes for p70/S6, STAT3, and STAT5; a second 
peak was seen for STAT5 at 24 hours (Figure 7A). A signifi-
cant inhibition of activation-induced STAT3 phosphorylation 
was observed when oATP was added to the culture (Figure 
7E), whereas the phosphorylation of JNK/SAPK1, p70/S6, or 
STAT5 in CD4+ T cells was unaffected (Figure 7B through 7D, 
respectively). We then confirmed by Western blot that oATP 
dose-dependently inhibits STAT3 phosphorylation (Figure 7F). 
To demonstrate that the effect of oATP is STAT3-phosphory-
lation-inhibition dependent, we tested the effect of Colivelin 
treatment, a peptide that promotes STAT3 phosphorylation36,37 
in an add-back experiment. We first confirmed that Colivelin 
(Col) was able to restore the activation-induced phosphoryla-
tion of STAT3 in a dose-dependent manner in oATP-treated 
CD4+ T cells by Western blotting (Figure 7G). Moreover, in an 
ELISPOT assay, in which naïve CD4+ T cells were stimulated 
with 0.5 µg/mL anti-CD3-Ig and anti-CD28-Ig, treatment with 
Colivelin was shown to significantly revert oATP-mediated 
suppression of IFN-γ–producing cells (Figure 7H). The effect 
of oATP and Colivelin on STAT3 phosphorylation and T-cell 
function was also evaluated following cardiac transplanta-
tion. BALB/c hearts were transplanted into C57BL/6 mice, 
and STAT3 phosphorylation was assessed by Western blot in 
CD4+ T cells isolated from splenocytes of mice 7 days after 
transplantation. oATP-treated mice displayed reduced levels 
of phosphorylated STAT3 in comparison with untreated mice, 
and, paralleling the results obtained in vitro, the use of Coliv-
elin was able to reestablish STAT3 phosphorylation in CD4+ 
T cells of oATP-treated mice (Figure 7I and 7J). From a func-
tional point of view, the use of Colivelin greatly abrogated the 
effect of oATP on allograft survival (Figure 7K). These data 
demonstrate that P2X7R signaling is crucial for T-cell activa-
tion and Th1/Th17 generation and that this effect is STAT3 
dependent.
In Vivo Short-term P2X7R Targeting Prevents 
Coronary Vasculopathy in a Model of Chronic 
Heart Cardiac Transplant Rejection
To evaluate the importance of P2X7R signaling and targeting in 
a clinically relevant setting, we tested the effect of oATP treat-
ment in a model of cardiac transplant chronic rejection (bm12 
donors to C57BL/6 recipients). In this model, C57BL/6 mice 
do not acutely reject bm12 cardiac allografts, but transplanted 
hearts develop transplant-associated coronary vasculopathy. 
Cardiac allograft pathology was assessed 40 days after trans-
plantation of bm12 hearts into C57BL/6 mice. Advanced cor-
onary vasculopathy and severe lymphocyte and macrophage 
interstitial and vascular infiltration were observed in untreated 
mice (Figure 8A1 through 8A4) in comparison with oATP-
treated mice (Figure 8B1 through 8B4), which displayed only 
mild cellular infiltration and the absence of coronaropathy, as 
well (Figure 8C and 8D, respectively). oATP-treated mice also 
showed a reduced number of IFN-γ–producing cells (Figure 
8E) and an increased number of IL-4–producing cells (Figure 
8F) in an ELISPOT assay when splenocytes were challenged 
with donor antigens.
Discussion
The introduction of novel immunosuppressive drugs has led 
to significant improvement in short-term cardiac transplant 
survival rates but has been unable to significantly improve 
allograft survival in the long-term1,2 Furthermore, current 
immunosuppressive regimens are associated with multiple 
complications, including cancer, opportunistic infections, dia-
betes mellitus, kidney failure, and hypertension.2–4 To improve 
transplantation outcomes, it is therefore critical to continue 
the development of novel strategies to lessen the need for life-
long immunosuppression and to achieve stable graft accep-
tance. We thus studied the role of the ionotropic purinergic 
P2X receptors (a family of receptors with largely unknown 
function in the alloimmune response) in cardiac transplant 
rejection and tolerance.
Aside from signal 1 (TCR engagement) and signal 2 
(costimulatory molecule interaction), soluble signals have 
also been recognized as major players in T-cell activation; 
we predicted that ATP would exert a fundamental role in the 
context of allograft organ rejection, in particular, in the first 
phase after transplantation when it could be released in marked 
amounts by necrotic or ischemic cells. Among all P2XsR, our 
data show that P2X7R is specifically upregulated during the 
alloantigen response in the graft and is expressed by virtually 
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all T cells infiltrating the graft. On the contrary, P2X1R and 
P2X4R are similarly increased in both syngrafts and allografts, 
and their upregulation may thus be more related to ischemia 
reperfusion injury and to posttransplant inflammation than 
specifically to the alloantigen response. It is noteworthy that 
we found P2X7R to be upregulated in T cells infiltrating 
cardiac transplants during clinical acute rejection, confirming 
the relevance of the P2X7R pathway in patients undergoing 
heart transplantation. In vivo, short-term P2X7R targeting 
with oATP robustly promoted long-term cardiac transplant 
survival in 80% of the recipients in a fully mismatched model 
of heart transplantation; moreover, oATP was able to inhibit the 
development of coronary vasculopathy in a chronic model of 
cardiac rejection. oATP was initially and primarily described as 
a P2X7R inhibitor,28 and, although recent articles have pointed 
to a broader effect of oATP as an inhibitor of other purinergic 
receptors,20 oATP remains to date the most well-characterized 
and effective drug to target in vivo P2X7R.38,39 The relative 
ineffectiveness of oATP treatment in P2X7R−/− mice appears to 
confirm that, although additional inhibition of other purinergic 
receptor may be present, there is a more restricted P2X7R-
mediated effect in our model; moreover, our in vitro data show 
that, at the concentration used, oATP does not (at least not 
completely) inhibit other P2XsR. P2X7R targeting is associated 
with a reduction in Teff and Th17 cells, which are known to be 
highly relevant to the alloimmune response, and we observed a 
reduction in the Th1/Th17 lymphocytic infiltrate. Inhibition of 
the antigraft effector T-cell compartment (Th1 and Th17) may 
Figure 7. Peak phosphorylation (assayed by Luminex) of JNK/SAPK1 was evident at 30 minutes after anti-CD3-Ig and anti-CD28-Ig 
stimulation in CD4+ T cells, whereas peaks in p70/S6, STAT3, and STAT5 phosphorylation were evident at 60 minutes; a second peak of 
phosphorylation for STAT5 was evident at 24 hours (A) (shown as MFI [mean fluorescence intensity]). P2X7R targeting via oATP treatment 
inhibited activation-induced STAT3 phosphorylation (n=3, **P<0.01 versus Control, E), whereas target of P2X7R had no effect on phos-
phorylation of JNK/SAPK1 (B), p70/S6 (C), or STAT5 (D). Western blot analysis confirmed reduced STAT3 phosphorylation dose depend-
ently with oATP treatment (F; representative of 3 different experiments). Colivelin (Col) prevented oATP-mediated inhibition of STAT3 
phosphorylation (G) and rescued CD4+ T cells from oATP-mediated suppression of IFN-γ production (n=8, ***P<0.001 versus Colivelin[−]/
oATP[−]; ##P<0.01 versus Colivelin[−]/oATP[+]; H). In our allogeneic model of cardiac transplantation, oATP treatment inhibited STAT3 
phosphorylation in CD4+ T cells (I and J). Colivelin restored STAT3 phosphorylation on CD4+ T cells (I and J) and significantly impaired the 
prolongation of cardiac transplant survival associated with oATP treatment (K; **P<0.01 and ***P<0.001 versus Untreated; ##P<0.01 ver-
sus oATP+Colivelin). oATP indicates periodate-oxidized ATP; and IFN-γ, interferon γ.
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thus be responsible for the observed long-term graft function. 
Although P2X7R inhibition has been related to a Th17-to-
Treg shift in in vitro assays23 and in a model of inflammatory 
bowel disease,14 flow cytometric analysis of treated mice 
does not support a clear expansion of the Treg compartment 
(observed only later after treatment) in our model. In contrast, 
our adoptive transfer experiments show an inhibition of the 
antigraft effector T-cell compartment and demonstrate, as well, 
a state of anergy toward graft antigens in treated mice, which 
is likely responsible for the observed long-term graft survival. 
Anergy toward alloantigens does not seem to be related to 
a state of chronic immunosuppression, as demonstrated by 
the preserved anti-ovalbumin response after immunization, 
which is particularly applicable to the clinical setting. From 
a molecular point of view, targeting P2X7R appears to be a 
result of activation-mediated STAT3 phosphorylation, given 
the reduced level of phosphorylated STAT3 following oATP 
treatment. Furthermore, Colivelin treatment, which restores 
STAT3 phosphorylation, reverts, although not completely, the 
effect of in vitro and in vivo oATP treatment, showing that 
other pathways may be affected by oATP.14,18 STAT3 is a well-
known transcription factor with multiple roles in mediating 
T-cell activation and proliferation.22,40,41 Our in vitro and in 
vivo data point to a novel axis in T-cell activation, which links 
ATP-P2X7R-STAT3 and activation of the antigraft effector 
T-cell compartment (Th1 and Th17 cells), which can be 
inhibited by the use of oATP. The centrality of this pathway 
at the crossroads of T-cell activation and differentiation is 
further demonstrated by the transduction of P2X7R on T 
cells and the associated effects of greater activation and Th1/
Th17 differentiation. The P2X7R pathway in T cells is highly 
important in the context of cardiac transplant rejection and 
may synergize with the P2X7R pathway in antigen-presenting 
cells18 to promote graft rejection. Willhem and colleagues 
have recently described a role for P2X7R in graft-versus-host 
disease18 by using the P2X7R−/− model; in comparison, (i) we 
tested a pharmacological inhibitor of P2X7R, which is more 
clinically relevant; (ii) we tested the effect of P2X7R targeting 
in 2 different models of solid-organ transplantation (ie, the acute 
and the chronic rejection model); (iii) we demonstrated a direct 
effect of P2X7R inhibition on T cells, which is independent of 
the inhibitory effect on antigen-presenting cell function; (iv) 
we showed that the effect of P2X7R targeting is mediated 
by an inhibition of the T-cell effector compartment more 
than by an expansion of the regulatory T-cell compartment; 
(v) we highlight the necessity of exercising some caution in 
the analysis of data by using P2X7R−/− mice given that the 
upregulation of other P2XsR (in the knock-out mouse, but 
not during pharmacological targeting) may partially obscure 
P2X7R function. On the NIH clinical trials web site (http://
www.clinicaltrials.gov), nearly 80 clinical trials are registered 
to promote tolerance in transplantation. None of these trials 
Figure 8. Bm12 hearts were transplanted in C57BL/6 recipients, and histological analysis of the transplants was performed at day 40 
after transplantation. Hematoxylin and eosin (H&E) and elastin staining showed advanced intimal proliferation and vascular occlusion of 
the arteries in untreated mice (A1 and A2), whereas preserved vessel morphology was observed in oATP-treated mice (B1 and B2). Mas-
sive vascular and parenchymal T cell (A3) and macrophage (A4) infiltration was seen in untreated mice, but not in oATP-treated mice (B3 
and B4). Semiquantification of coronary vasculopathy (C) and infiltration (D) confirmed that cardiac transplants were protected by oATP 
treatment (n=3; **P<0.01 versus Untreated day 40). Results of an ELISPOT assay showed reduced numbers of IFN-γ–producing cells (E) 
and increased numbers of IL-4–producing cells (F) among recipient splenocytes challenged with donor antigens in oATP-treated mice 
(n=3; *P<0.05; **P<0.01 versus Untreated day 40). ELISPOT indicates enzyme-linked immunosorbent spot; oATP, periodate-oxidized ATP; 
IFN-γ, interferon γ; and IL-4, interleukin 4.
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is specifically aimed or designed to target P2X7R-mediated 
alloimmunity, yet our results clearly indicate the need for novel 
therapeutic options for transplantation. We envision P2X7R-
mediated immunity as a novel pathway for cardiac transplant 
rejection. Indeed, a P2XR-targeting strategy has considerable 
translational potential, because novel anti-P2X7R inhibitors 
are available for clinical use (eg, oATP, CE 224,535, AZD9056, 
and GSK1482160). Short-term P2X7R targeting at the time 
of transplantation may prove to be valuable in the clinical 
setting by promoting cardiac transplant acceptance, lessening 
the need for chronic immunosuppression, and preventing the 
development of coronary graft vasculopathy.
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CLINICAL PERSPECTIVE
Heart transplantation is a lifesaving procedure for patients with end-stage heart failure and provides a better survival and 
quality of life in comparison with medical treatment or device-based therapies. Recently, advances in immunosuppression 
and improved clinical care have enhanced the early survival of patients with cardiac transplants. However, >20% of patients 
do not survive beyond 3 years, and those who survive are afflicted with the long-term complications associated with chronic 
immunosuppression (eg, posttransplant diabetes mellitus, coronary vasculopathy, nephropathy, infections, and malignancies). 
To improve transplantation outcomes and lessen the need for life-long immunosuppression, it is crucial to continue the 
development of novel immunomodulatory strategies. Short-term targeting of the purinergic receptor P2X7 (P2X7R) may 
provide a novel therapeutic opportunity. Soon after transplantation, purine ATP is released by necrotic cells and causes the 
activation of graft-infiltrating T cells, which sense ATP by the highly expressed receptor P2X7R. Our data show that short-
term P2X7R targeting with periodate-oxidized ATP robustly promotes, in a fully-mismatched model of acute rejection, 
long-term cardiac transplant survival in 80% of recipients, with preservation of immunocompetence. Moreover, periodate-
oxidized ATP inhibits the development of coronary vasculopathy in a model of chronic rejection. Nearly 80 clinical trials are 
registered on the National Institutes of Health web site to promote long-term graft function, and none of these is designed to 
target P2X7R-mediated alloimmunity. Because novel P2X7R inhibitors are available for clinical use (eg, periodate-oxidized 
ATP, CE-224,535, AZD9056, and GSK1482160), short-term P2X7R targeting may have considerable translational potential 
by promoting cardiac transplant acceptance, thereby lessening the need for chronic immunosuppression and preventing the 
development of coronary vasculopathy.
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ONLINE SUPPLEMENTAL MATERIAL 
IMMUNOLOGICAL METHODS 
Adoptive transfer of C57BL/6 cells 
20x106 splenocytes obtained from naïve C57BL/6 mice or from oATP-treated 
transplanted mice at day 100 after transplantation, or 10x106 obtained from naïve 
C57BL/6 mice and 10x106 obtained from oATP-treated mice, were injected into BALB/c 
cardiac-transplanted C57BL/6 Rag1-/- mice, and survival was assessed as described. 
Adoptive transfer of TCR-Tg cells 
3x106 ABM TCR-Tg CD4+ T cells were injected into bm12 cardiac-transplanted 
C57BL/6 Rag1-/- mice, and splenocytes were harvested 7 days post-transplant. The total 
numbers of ABM TCR-Tg CD4+ T cells, Teffs, and Th17 cells were assessed.  
Cell purification and CFSE labeling 
CD4+, CD8+, and CD4+CD25- T cells were isolated from splenocytes using MACS 
microbeads (Miltenyi Biotec, Auburn, CA). CFSE labeling was performed using the 
Vybrant® CFDA SE Cell Tracer Kit (Invitrogen, Carlsbad, CA). 
ELISPOT 
An ELISPOT assay was used to measure the number of IFN-γ-/IL-4-producing cells (BD 
Biosciences, San Jose, CA). Allogeneic splenocytes (BALB/c) or anti-CD3- and anti-
CD28-Ig (BD Biosciences, 0.5 µg/ml each) were used to stimulate 1x106 responder 
splenocytes or 2x105 T cells (C57BL/6)1. Spots were counted using an Immunospot 
analyzer (Cellular Technology Ltd., Cleveland, OH). In a similar experiment, expression 
levels of P2XsR were assessed by quantitative real-time PCR. 
Ovalbumin immunization 
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Ovalbumin peptide (Sigma Aldrich, St. Louis, MO) emulsified in complete Freund's 
adjuvant (Sigma Aldrich) was injected once (100 µg/mouse i.p.). Splenocytes were 
collected and used in in vitro assays after rechallenge with 1 µmol/L ovalbumin peptide 
for 24 h2. 
T-cell differentiation assay 
Naive sorted CD4+CD25- T cells (Th0) were isolated and activated for 5 days with 1 
µg/ml of plate-bound anti-CD3 and anti-CD28 antibodies (BD Biosciences). Cultures 
were supplemented with either 5 ng/ml mIFN-γ and 10 µg/ml of anti-IL-4 mAb for Th1 
differentiation, or with 10 µg/ml of anti-IFN-γ mAb and anti-IL-4 mAb, 5 ng/ml of 
mTGF-β and 20 ng/ml of rIL-6 for Th17 differentiation. Proteins and antibodies were 
purchased from R&D Systems (Minneapolis, MN) and BD Biosciences.  
P2X7R transfection of T cells 
The hP2X7R cDNA construct (kindly provided by Dr. Gary Buell [Ares-Serono Research 
Laboratories, Geneva, Switzerland] and Dr. Francesco Di Virglio [University of Ferrara, 
Ferrara, Italy]) was inserted into the pMY-IRES-GFP plasmid (Cell BioLabs, Inc., San 
Diego, CA). The Platinum-E Retroviral Packaging cell line was transfected with the 
pMY-IRES-GFP plasmid expressing P2X7R using Lipofectamine 2000 (Invitrogen), and 
supernatant was collected. T cells were activated in the presence of Mouse T-Activator 
CD3/CD28 Dynabeads (Invitrogen), and viral supernatant was added.  
 
SUPPLEMENTAL FIGURE LEGEND 
Figure S1. P2XsR expression was tested in CD4+ T cells after 24 hours of anti-CD3-
Ig/anti-CD28-Ig stimulation with or without 100µM oATP. No differences in the 
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expression levels of P2X1R, P2X3R, P2X4R, P2X5R, or P2X7R were observed (n=3, 
A), while levels of P2X2R and P2X6R remained undetectable.  
 
Figure S2. Greater P2X7R expression was observed in pmY-P2X7R-transfected T cells 
compared to pmY-mock-transfected T cells (A). Anti-CD3-Ig/anti-CD28-Ig-stimulated 
untransfected (Control), pmY-P2X7R- and pmY-mock-transfected CD4+ T cells were 
tested in an ELISPOT assay. An increased number of IFN-γ-producing CD4+ T cells was 
observed in pmY-P2X7R-transfected cells (n=5, ***p<0.001 vs. Control and pmY-mock-
transfected; B). In our Th1/Th17 differentiation assay, untransfected pmY-P2X7R- and 
pmY-mock-transfected naïve Th0 cells were assessed for T-bet and ROR-γ expression. 
Higher T-bet expression (C, quantified in D, representative of 3 different experiments) 
and ROR-γ expression (E, quantified in F, representative of 3 different experiments) were 
observed by western blotting of pmY-P2X7R-transfected cells.  
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